Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,457.00    6.00 (0.41%)
Bid:
1,464.00
Ask:
1,466.00
Spread: 2.00 (0.137%)
Market Cap: £3.08b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Annual Information Update

5 Apr 2013 11:03

RNS Number : 6906B
Hikma Pharmaceuticals Plc
05 April 2013
 



 

Annual Information Update

London, 5 April 2013. In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the period. The information referred to in this Update was up to date at the time the information was published, but some information may now be out of date.

Stock Exchange Announcements

Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the Company's market news section on the London Stock Exchange website at (http://www.londonstockexchange.com/prices-and-news/stocks/stocks-and-prices.htm) or from the press releases page on the Company's website at (http://www.hikma.com/investorrelations/rns/). The Stock Exchange announcements made during the period were:

Date

Headline

25/03/2013

Director/PDMR Shareholding

13/03/2013

Preliminary Results

01/03/2013

Response to unsolicited enquiries

21/01/2013

Additional Listing

09/01/2013

Acquisition

03/01/2013

Total Voting Rights

27/12/2012

Holding(s) in Company

13/12/2012

Product Launch

27/11/2012

Building Public Trust Awards - Highly Commended

12/11/2012

Total Voting Rights

02/11/2012

Interim Management Statement

01/11/2012

Holding(s) in Company

11/10/2012

Injectables Analyst and Investor Day USA

10/10/2012

Blocklisting Interim Review

10/10/2012

Total Voting Rights

04/10/2012

Dividend Declaration

16/08/2012

Half Yearly Report

08/08/2012

Holding(s) in Company

06/07/2012

Total Voting Rights

03/07/2012

Holding(s) in Company

29/06/2012

Director/PDMR Shareholding

25/06/2012

Director/PDMR Shareholding

21/06/2012

Director/PDMR Shareholding

06/06/2012

Total Voting Rights

18/05/2012

Director/PDMR Shareholding

17/05/2012

Result of AGM

17/05/2012

Interim Management Statement

01/05/2012

Holding(s) in Company

20/04/2012

Holding(s) in Company

16/04/2012

Annual Information Update

13/04/2012

Annual Financial Report & AGM Notice

All of the above announcements were also made by the Company via the Nasdaq Dubai stock exchange CANDI system. These announcements may be viewed and downloaded from the Nasdaq Dubai website (www.candi.nasdaq.com).

Documents filed with the Financial Services Authority

The Company has filed the following documents with the Financial Services Authority ("FSA") visa the National Storage Mechanism over the previous 12 months. These documents are available at http://www.hemscott.com/nsm.do or at the Company's registered office.

Date

Document

13 April 2012

Annual Report and Accounts 2011

13 April 2012

Notice of 2012 Annual General Meeting

13 April 2012

Proxy forms for the 2012 Annual General Meeting

Documents filed with Companies House

The Company submitted filings to the Registrar of Companies in England and Wales as detailed in the table below.

Date Filed

Form

Description

12/11/2012

SH01

Statement of Capital GBP 19,697,811

10/10/2012

SH01

Statement of Capital GBP 19,697,141

07/09/2012

AR01

Annual Return, No Member List

09/07/2012

SH01

Statement of Capital GBP 19,686,391

15/06/2012

RES10

Authorised Allotment of Shares and Debentures

15/06/2012

AA

Group of Companies' Accounts made up to 31/12/11

06/06/2012

SH01

Statement of Capital GBP 19,682,241

21/05/2012

RES10

Authorised Allotment of Shares and Debentures

11/04/2012

AP03

Secretary Appointed, Peter Alexander Speirs

11/04/2012

TM02

Secretary Appointment Terminated, Henry Knowles

Copies of all these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House Direct at www.direct.companieshouse.gov.uk.

Further Information

Copies of all documents can be obtained from the Company at the registered office which is located at 13 Hanover Square, London W1S 1HW.

 

Peter Speirs

Company Secretary5 April 2013

 

- ENDS -

 

 

Enquiries:

 

Hikma Pharmaceuticals PLC

 

Peter Speirs

Company Secretary

 

+44 20 7399 2670

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AIUBELFBXZFBBBB
Date   Source Headline
14th Jul 201511:12 amRNSTotal Voting Rights
18th May 201510:30 amRNSHikma Founder Samih Darwazah passes away
18th May 201510:00 amRNSDirector/PDMR Shareholding
15th May 20151:25 pmRNSDirector/PDMR Shareholding
14th May 20154:27 pmRNSResult of AGM
14th May 20157:00 amRNSAGM Trading Update
12th May 20159:00 amRNSHikma launches caffeine citrate injection
15th Apr 20159:47 amRNSHolding(s) in Company
10th Apr 20153:19 pmRNSTotal Voting Rights
10th Apr 20157:00 amRNSDirector/PDMR Shareholding
9th Apr 201511:16 amRNSAnnual Information Update
9th Apr 201510:51 amRNSAnnual Financial Report
7th Apr 20153:03 pmRNSBlocklisting Interim Review
1st Apr 20155:13 pmRNSHikma prices debut $500 million five-year eurobond
31st Mar 20153:27 pmRNSStabilisation Notice
25th Mar 201512:23 pmRNSFixed income investor meetings
19th Mar 20151:45 pmRNSDirector/PDMR Shareholding
13th Mar 201511:34 amRNSHolding(s) in Company
11th Mar 20157:00 amRNSFinal Results
27th Jan 20152:13 pmRNSHikma Delivers Insights at World Economic Forum
23rd Jan 201511:44 amRNSDirector Declaration
21st Jan 201511:19 amRNSNotification of major interest in shares
15th Jan 201510:04 amRNSBlocklisting Interim Review
12th Jan 20157:00 amRNSHikma to launch colchicine 0.6mg capsules
7th Jan 201511:11 amRNSTotal Voting Rights
12th Nov 201412:14 pmRNSDirector/PDMR Shareholding
11th Nov 20141:22 pmRNSTotal Voting Rights
7th Nov 201411:12 amRNSNotification of major interest in shares
6th Nov 20147:00 amRNSDirectorate Change
6th Nov 20147:00 amRNSInterim Management Statement
24th Oct 20147:00 amRNSHikma announces receipt of Warning Letter from FDA
20th Oct 20145:18 pmRNSDirector/PDMR Shareholding
10th Oct 201411:44 amRNSStatement re Colchicine
10th Oct 20147:00 amRNSDirector/PDMR Shareholding
6th Oct 20143:58 pmRNSBlocklisting Interim Review
6th Oct 201411:23 amRNSTotal Voting Rights
30th Sep 20146:13 pmRNSRegulatory Approval Colchicine
17th Sep 20147:00 amRNSAcquisition
20th Aug 20144:00 pmRNSDividend Declaration
20th Aug 20147:00 amRNSInterim Results
7th Aug 20144:05 pmRNSNotice of Interim Results Announcement
28th Jul 20149:01 amRNSDirector/PDMR Shareholding
24th Jul 20149:08 amRNSAcquisition
15th Jul 20143:35 pmRNSAcquisition
14th Jul 20143:41 pmRNSTotal Voting Rights
27th Jun 20144:07 pmRNSDirector/PDMR Shareholding
23rd Jun 20142:20 pmRNSDirector/PDMR Shareholding
11th Jun 20143:11 pmRNSDirector/PDMR Shareholding
10th Jun 20145:13 pmRNSTotal Voting Rights
29th May 20149:45 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.